GBAPOLSKA

ANALYTICAL LABORATORIES
microbiology - physicochemistry - sensory

GBA POLSKA Sp. z o.o.
Member of GBA GROUP
ul. Mochtyńska 65, 03-289 Warsaw, Poland

TEST REPORT No: K/0/11/2025/67/F/NN/1/EN

Customer: Beta Alg Biyoteknoloji Ltd. Şti. 14300 Merkez / BOLU, Kültür Mahallesi, Çakmaklar Caddesi, Teknokent Ana Bina Blok No: 2 İç Kapı No:47

Order No: K/0/11/2025/67

Material/product tested:	**Cosmetics**
Sample collection address:	35930 Çeşme / İzmir, ul.Sakarya Mah. 3077 Sokak No:7
Product name:	***Sepiida Sun Screen*** **Date*: 04 November 2025**
Producer:	*no data*
Date of production:	*no data*
Lot number:	*no data*
Notes on the sample:	lack

Sampling according to: -
Samples transported by: Shipping
Received by: GBA POLSKA employee no: 2744

Sample no: 5559/11/25 Sample condition: correct Analysis start date: 17-11-2025 Analysis end date: 21-11-2025

Lab.	Analyzed parameter	Unit	Accred.	Test method	Requirement	Result	U
Ł	Dermatological patch test (15 subjects, normal skin, supervision of a dermatologist)	-	NN	PB-8/LK ed.1 dated 17.12.2020	no requirements	in attachment no, F/5559/11/25	

Date* - depending on the method of obtaining the sample by GBA POLSKA, it is the date of: collection (when the sample is collected only by a GBA POLSKA employee) or receipt (when the sample is collected from the Customer by a GBA POLSKA employee, is delivered by a courier company or delivered personally by the Customer).
U - expanded measurement uncertainty at the level of confidence app. 95% and the coverage factor k=2, does not take into account the sampling uncertainty, except when indicated in the remarks. Measurement uncertainty is provided when it is important for the reliability of test results or compliance with requirements/specifications and at the request of the Customer. The "test results" lower or higher than the measuring ranges of the methods are presented as "<value of the lower limit of the measuring range " or "> value of the upper limit of the measuring range", respectively. These values provide information about the research results. If expanded uncertainties are given with these test results, they apply to the lower or upper limit of the measuring range of the method.
The results refer only to the tested samples (sampled or received - in accordance with the information presented in the Test Report).
The information in italics included in the Test Report was provided by the Customer. The laboratory is not responsible for this information. The laboratory is not resposible for the method of sampling and the representativeness of the samples provided by the Customer for testing.
The Test Report without the written approval of the Laboratory shall not be reproduced except in full.
The Laboratory does not store the samples after testing, unless otherwise agreed with the Customer.
Place of performance of the tests ("Lab."): Ł - Łajski, ul. Kościelna 2a, 05-119 Legionowo, L - ul. Doświadczalna 50a, 20-280 Lublin, M - ul. Fabryczna 7, 41-404 Mysłowice, P1 – ul. Kazimierza Tymienieckiego 34, 60-681 Poznań, P2 – ul. Jasielska 16a, 60-476 Poznań, W – ul. Ząbkowska 18, 03-735 Warszawa, PS - in situ measurement.

NOTE: Original Test Report is issued in electronic form with the *.pdf extension, signed with a qualified electronic signature. Therefore, all prints, unless certified as true copies, are copies.

Remarks:

Created on:	**Authorized result:**	**Authorized Test report:**
27-11-2025	GBA POLSKA employee no: 2566	Cosmetics specialist GBA POLSKA employee no: 2550

Signed with a qualified electronic signature

Report prepared in a single copy **Original of PDF: Customer, copy of PDF to: Laboratory archive**

The end of the Test Report

APPENDIX TO THE TEST REPORT

Appendix No F/5559/11/25/EN

sample/samples No 5559/11/25
order No K/0/11/2025/67

DERMATOLOGICAL (PATCH TEST)	
Product name	**Sepiida Sun Screen**
Date of test start	**17-11-2025**
Date of test end	**21-11-2025**
Report date	**24-11-2025**

Purpose of the study

Assessment of irritation / allergenic effect of the product

Microbial purity testing

The results of microbiological purity of the product provided by the Sponsor

Product characteristics

Product purpose: **Skin care**

How to use: **No date**

Qualitative product composition

INCI composition (*): DIW, Glycerol, Triethanolamine, Stearic Acid, Methyl Paraben, Liquid Paraffin, Cetosteryl Alcohol, Propyl Paraben, Melanin Nanoparticles, Astaxanthin

(*) - The Customer bears full responsibility for compliance of samples delivered for testing with the declared qualitative composition. The Laboratory does not analyse the composition in regard to the current regulatory requirements.

The scope of tests in accordance with:

» The general principles of medical ethics in clinical research coming from Declaration of Helsinki (June 1964) and its successive amendments
»Regulation of the European Parliament and of the Council (WE) No. 1223/2009 dated 30.11.2009 regarding cosmetic products
» COLIPA Guidelines
„Product test Guidelines for the Assessment of Human Skin Compatibility 1997"
„Guidelines for the Evaluation of the Efficacy of Cosmetic Products 2008"
»Memorandum on use of Human Data in risk assessment of skin sensitisation – SCCS/1567/15
»The SCCS Notes of Guidance for the Testing of Cosmetic Ingredients and their Safety Evaluation 12th Revision – SCCS/1647/22
»European Regulation (EU) 2016/679 and its successive amendments on the protection of individuals with regard to the processing of personal data and free movement of such data.

Testing methodology

The study was conducted in accordance with the Research Procedure SOP-MET-029.
The tested substance is applied to the skin using special chambers fixed on a hypoallergenic adhesive (chambers IQ Ultimate®). The chambers are filled with the substances being tested and then affixed to the skin of the back in the shoulder blade area. During the tests, one cannot soak his/her back and should avoid sudden movements and sweating. Patches with test substances are left on the test skin for 48 hours.
After the removal of the adhesives with the chambers, the excess test substances are removed by pressing a paper towel onto the skin. The skin reaction is assessed after 15 minutes after removing the adhesives (after 48 hours) and after 72 hours according to a scale that is consistent with the scale generally accepted in dermatological tests. Additionally, in the case of positive skin reactions, the skin reaction is also assessed after 96 hours and on the following days until symptoms resolve.

Evaluation parameters

The patch test readings were made according to the International Contact Dermatitis Research Group(ICDRG)
Graphical scale of the ICDRG patch test reading:



(–) negative reaction	no reaction
(?) doubtful reaction	subtle erythema, palpably undetectable erythematous spot

(+) weak reaction	palpable erythema, suggestive of mild edema / infiltration, clumping may occur, no blisters
(++) strong reaction	increased swelling, infiltration, clots, blisters
(+++) very strong reaction	blisters, erosions, ulceration
(IR) irritative reaction	shiny skin, dry skin, pimples, erythema

A product can be classified as non-irritant and compliant with the Skin Compatibility Test if the mean of the reactions does not exceed 0,10 in a group of test persons, according to the table below:

IRRITATION POTENTIAL	
0,00 ≤ average ≤ 0,10	POSITIVE REPORT

RATING SCALE		
Negative result	0	0
Doubtful reaction	?	0,5
Weak reaction	+	1
Strong reaction	++	2
Very strong reaction	+++	3

Selection of Study Participants

The selection of Study Participants was carried out in accordance with internal procedure, SOP ORG 001, taking into account:
»Helsinki Declaration of 1964 (with later additions)
»Current Polish and European legal regulations
»Cosmetics Europe guidelines using the inclusion and exclusion criteria

20 skin-healthy volunteers were chosen to become subjects in the study.
Volunteers filled out a detailed survey regarding their lifestyle, the current state of health, past illnesses, eating habits, medicines and the use of stimulants and the survey on coexisting skin problems (allergy issues included). The volunteers were selected from this general panel on the basis of inclusion criteria and non-inclusion criteria specific to the study and on their ability to respect the constraints required by the study methodology. The application of the patch tests was preceded by a dermatology examination assessing, above the others, the type of skin and the presence of any pathological changes on the skin.

GENERAL INCLUSION CRITERIA	Healthy subject
	Declaring to have a health coverage
	Signing an „informed consent form” for this study
	Skin without irritation and changes requiring pharmacological treatment
	Cooperative subject, aware of the necessity and duration of controls, free to ensure the visits to the investigating center

SPECIFIC INCLUSION CRITERIA	Gender	*Female and male*
	Age	*18+*
	Skin type	*Normal*

	Skin phototype (Fitzpatrick scale)	*I-IV*
	Other	Regular or occasional users of body cosmetics products.

GENERAL NON INCLUSION CRITERIA	Subjects who use any treatment on the studied zone
	Being in exclusion period
	Pregnant or breastfeeding woman or woman planning a pregnancy during the study
	Subject having a skin disease on the studied zone
	Subject exhibiting or having a known history of acute or chronic dermatological, medical and/or physical conditions that could influence the outcome of the test
	Subject considered by the investigator to be likely not compliant with the study methodology
	Subject undergoing treatment with antihistamines, nonsteroidal anti-inflammatory agents, corticosteroids and/or any other medications that could have interfered with the results of this study.
	Subject planning the hospitalization during the study period

All volunteers selected for the study met the requirements for inclusion in the study and signed consent for conscious participation in the study, and were informed about the purpose of the study, how it was conducted and about possible side effects. The skin, where the patch tests were applied, was healthy and free of skin lesions.

Results

Volunteers characteristic					*Results after 48h*	*Results after 72h*
No.	*Sex*		*Age*	*Skin type*	*Skin reaction*	*Skin reaction*
1	F		23	N	(-)	(-)
2	F		47	N	(-)	(-)
3	F		45	N	(-)	(-)
4	F		45	N	(-)	(-)
5	F		61	N	(-)	(-)
6	F		22	N	(-)	(-)
7	F		53	N	(-)	(-)
8	F		61	N	(-)	(-)
9	F		53	N	(-)	(-)
10	M		33	N	(-)	(-)
11	F		49	N	(-)	(-)
12	F		41	N	(-)	(-)
13	M		37	N	(-)	(-)
14	F		24	N	(-)	(-)
15	F		37	N	(-)	(-)
16	M		28	N	(-)	(-)
17	M		50	N	(-)	(-)
18	F		63	N	(-)	(-)
19	F		68	N	(-)	(-)
20	F		46	N	(-)	(-)
	F	16	*Age min.*	22	*Irritant potential*	0
	M	4	*Age max.*	68		

Legend: F – female, M – male, N – normal, (-) – no skin reaction

SUMMARY

In the group of 20 people who underwent the study, no positive contact allergy or irritant reaction was observed after using the product. The irritation potential score is ≤ 0,10.

The lack of positive reactions indicates that the tested product does not show irritating and sensitizing effects in contact with the skin.

Based on the results of the tests performed, we conclude that the „Sepiida Sun Screen" product meets the requirements of the Skin Compatibility Test and may be estimated as non-irritant.

The issued opinion does not apply to people who are allergic to any of the components of the product under evaluation.

Prepared on:	Prepared:	Authorized:
24-11-2025	GBA POLSKA Employee no.: 3253	GBA POLSKA Employee no.: 2824

Authorized Results:

Dermatologist:

Signed by / Podpisano przez:
Dominika Aleksandra Perron-Płusa
Date / Data: 2025-11-28 16:35

Dr Dominika Perron-Płusa - Specialist in Dermatology and Venereology

The appendix from the research is signed with a qualified electronic seal of GBA Polska
The end of appendix